Patents Represented by Attorney Mary VanAtten

Find this attorney in the Justia Lawyer Directory

  • Lactams as modulators of chemokine receptor activity
    Patent number: 7338975
    Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
    Type: Grant
    Filed: February 11, 2004
    Date of Patent: March 4, 2008
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Percy H. Carter, Matthew E. Voss
  • Cyclic derivatives as modulators of chemokine receptor activity
    Patent number: 7338947
    Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma, processes for preparing and intermediates thereof.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: March 4, 2008
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Robert J. Cherney, Percy H. Carter, John V. Duncia, Daniel S. Gardner, Joseph B. Santella
  • Cyclic protein tyrosine kinase inhibitors
    Patent number: 7153856
    Abstract: Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
    Type: Grant
    Filed: May 26, 2005
    Date of Patent: December 26, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joel C. Barrish, John Wityak, Jagabandhu Das, Ping Chen, Derek J. Norris, Gary Schieven
  • Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
    Patent number: 7071333
    Abstract: The present invention provides for triazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, R4, and R5 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
    Type: Grant
    Filed: July 29, 2004
    Date of Patent: July 4, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald Combs, Charles M. Langevine, Yuping Qiu, Fred Christopher Zusi
  • Process for the manufacture of optically active 3-substituted lactams by asymmetric hydrogenation of 3-alkylidenelactams
    Patent number: 7015320
    Abstract: The present invention relates generally to processes for the efficient production optically active 3-substituted lactams of formula (I) process, comprising: contacting a compound of formula (II): with hydrogen under a suitable pressure in the presence of an iridium complex of the formula (R2)IrL+X? wherein L is a chelating diene, X is a non coordinating anion, and R2 is selected from
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: March 21, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: William A. Nugent, Tai Yue
  • N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
    Patent number: 6992091
    Abstract: The present application describes N-ureidoalkyl piperidines as modulators of chemokine receptors, or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: September 11, 2003
    Date of Patent: January 31, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: John V. Duncia, Daniel S. Gardner, Joseph B. Santella
  • Piperidine amides as modulators of chemokine receptor activity
    Patent number: 6984651
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: August 7, 2003
    Date of Patent: January 10, 2006
    Assignee: Bristol-Myers Squibb Pharma, Company
    Inventors: John V. Duncia, Joseph B. Santella, Dean A. Wacker, Wenqing Yao, Changsheng Zheng
  • Piperizinones as modulators of chemokine receptor activity
    Patent number: 6974869
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: December 13, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: George V. DeLucca
  • Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
    Patent number: 6969721
    Abstract: The present invention relates to tricyclic 2-pyridone compounds of formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: November 29, 2005
    Assignee: Bristol-Myers Squibb Pharma
    Inventors: James D. Rodgers, Haisheng Wang, Mona Patel, Argyrios Arvanitis, Anthony J. Cocuzza
  • Bicyclic and tricyclic amines as modulators of chemokine receptor activity
    Patent number: 6960666
    Abstract: The present application describes modulators of CCR3 of formula (I): A-E-NR1-G??(I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.
    Type: Grant
    Filed: May 11, 2004
    Date of Patent: November 1, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: John V Duncia, Joseph B Santella, III, Daniel S Gardner, Dean A Wacker
  • N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity
    Patent number: 6949546
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: September 27, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Soo S. Ko, James R. Pruitt, Dean A. Wacker, Douglas G. Batt
  • Cyanamide, alkoxyamino, and urea derivatives of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones as HIV reverse transcriptase inhibitors
    Patent number: 6946469
    Abstract: The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones of formula I: or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, wherein A is selected from NCN, NCONH2, and NOR9. The present invention relates to compounds which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: September 20, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jeffery W. Corbett, James David Rodgers
  • N-substituted heterocyclic amines as modulators of chemokine receptor activity
    Patent number: 6919356
    Abstract: The present application describes modulators of chemokine receptors of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: July 19, 2005
    Assignee: Bristol Myers Squibb Company
    Inventor: Douglas G. Batt
  • N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
    Patent number: 6919368
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: July 19, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Soo S. Ko, George V. Delucca, John V. Duncia, Ui Tae Kim, Dean A. Wacker, Changsheng Zheng
  • N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
    Patent number: 6906066
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: June 14, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Soo S. Ko, George V. Delucca, John V. Duncia, Joseph B. Santella, III, Dean A. Wacker, Paul S. Watson, Jeffrey G. Varnes, Wenqing Yao
  • N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
    Patent number: 6897234
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: May 24, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Soo Ko, George DeLucca, John Duncia, Ui Tae Kim, Joseph B. Santella III, Dean A. Wacker
  • N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
    Patent number: 6875776
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: April 5, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Soo S. Ko, Cheryl McArdle Clark, George V. DeLucca, John V. Duncia, Joseph B. Santella, III, Dean A. Wacker
  • Benzylcycloalkyl amines as modulators of chemokine receptor activity
    Patent number: 6864380
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: March 8, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Dean A Wacker, John V Duncia, Joseph B Santella, III, Daniel S Gardner
  • Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
    Patent number: 6844340
    Abstract: The present invention relates to tricyclic 2-pyrimidone compounds of formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: January 18, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventor: Christine M. Tarby
  • Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
    Patent number: 6774112
    Abstract: Crystalline complexes are obtained from a 1:1 or 2:1 mixtures of either the (D) or (L) enantiomer of natural amino acids and compounds of formula wherein R1, R2 and R2a are independently hydrogen, OH, OR5, alkyl, —OCHF2, —OCF3, —SR5a or halogen; R3 and R4 are independently hydrogen, OH, OR5b, alkyl, cycloalkyl, CF3, —OCHF2, —OCF3, halogen, —CONR6R6a, —CO2R5c, —CO2H, —COR6b, —CH(OH)R6c, —CH(OR5d)R6d, —CN, —NHCOR5e, —NHSO2R5f, —NHSO2Aryl, —SR5g, —SOR5h, —SO2R5i, or a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO2, or R3 and R4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO2; R5, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h and R5i are independently alkyl; R6
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: August 10, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventor: Jack Z. Gougoutas